Shire’s growth strategy is to focus on developing and marketing innovative specialty medicines for rare and specialty conditions to meet significant unmet patient needs. Mergers and acquisitions (M&A) have been a major driver behind Shire’s growth over the last two decades, providing much of our current product portfolio. M&A activity will continue to be a strategic priority as we look to build our pipeline and increase patient access to treatment in the future.
Strategy and Approach
Buying another company or product is always a major decision. A thorough due diligence process, to ensure we understand the opportunity and can identify and mitigate potential risks, is critical to a successful M&A strategy. We have key roles within Shire dedicated to this type of due diligence and have invested in training to ensure this is one of Shire’s core capabilities.
We focus not just on the company or product we want to acquire but how we will integrate them into Shire. The change that accompanies an acquisition can provide many new opportunities, but can also be challenging for some. We are committed to communicating openly with existing and new staff on the impact of any acquisition. We work thoughtfully to integrate new employees into the Shire organization in a way that makes them feel valued and ensures they understand our way of working, our expected standards of behavior and our approach to Responsibility. At the same time it is important to listen to and learn from our new colleagues. We are open to new ideas and strive to adopt and implement the best practices wherever they originate.